4DMT to acquire Aevitas asset for up to $140 million

Genetic Medicines company 4D Molecular Therapeutics (Nasdaq: FDMT) is to acquire Aevitas’ proprietary rights to its short-form human complement factor H (sCFH) asset for the treatment of complement-mediated diseases.

Under the terms of the agreement, 4DMT will make cash payments to the Fortress Biotech (Nasdaq: FBIO) subsidiary company totaling up to $140 million in potential late-stage development, regulatory and sales milestones. Single-digit royalties on net sales are also payable to Aevitas.

4DMT will also be responsible for license payment obligations to University of Pennsylvania, where the sCFH technology was co-invented and co-developed by Wenchao Song, a professor of pharmacology at the Perelman School of Medicine.